Huashen Technology plans to issue shares to its indirect controlling shareholder Yuanhong Biotech, raising total proceeds of no less than 300 million yuan and no more than 350 million yuan, all to be used to replenish working capital and repay borrowings. The issue price is 3.15 yuan per share, with the number of shares to be issued no less than 95.2381 million and no more than 111 million, fully subscribed by an enterprise controlled by the actual controllers, the couple Huang Mingliang and Ouyang Ping. The company's total operating revenue for 2025 was 545 million yuan, down 36.86 percent year-on-year, and the net loss attributable to the parent company was 320 million yuan, marking the second consecutive year of losses, with the loss margin sharply widening. The Shenzhen Stock Exchange has issued a review inquiry letter regarding this private placement, focusing on issues such as the continuous decline in performance.
Chengdu Huasun Group Inc LtdPlans to raise up to 350 million yuan via private placement to repay debt and replenish working capital, with performance declining sharply.
As the indirect controlling shareholder and underwriter of the private placement, it will acquire shares at a fixed price.